Ipamorelin Research: Mechanism, the Human Trial, and Stack Comparisons
Before the details
Here is the Ipamorelin research in plain language. Ipamorelin is a man-made peptide that flips a switch — the ghrelin receptor — on the pituitary gland, which then releases a burst of growth hormone. What makes it interesting to scientists is that it does this cleanly: lots of growth hormone, almost no cortisol or prolactin [1]. The strongest data are old and preclinical (rats and pigs in the late 1990s), plus one human study that measured how fast it clears the blood [2]. The one human trial that tested whether it helps anything — recovery of bowel function after surgery — did not work [3]. The newest published animal study, in ferrets in 2024, showed it blunted chemotherapy weight loss but did nothing for nausea [5]. Below, each major finding gets its own section, with the species and dose stated and the source cited.
What is ipamorelin peptide
Ipamorelin is a synthetic pentapeptide — sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C₃₈H₄₉N₉O₅, ~711.9 Da, CAS 170851-70-4. It was derived from the earlier peptide GHRP-1 by removing a central Ala-Trp dipeptide [1]. The non-natural amino acid Aib (alpha-aminoisobutyric acid) at position 1, plus the D-form residues, make it resistant to the enzymes that would otherwise chew it up. Functionally it is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) — it mimics the natural hormone ghrelin at that receptor to release growth hormone [1]. It is wholly synthetic and is not a peptide the human body makes.
Mechanism: a clean growth-hormone pulse
Ipamorelin binds GHS-R1a (the ghrelin receptor) on pituitary somatotrophs — the GH-producing cells — and triggers GH release through the Gq/PLC pathway, which raises intracellular calcium [1]. The headline result from the founding 1998 study: in primary rat pituitary cells, anaesthetized rats, and conscious swine, ipamorelin released GH as potently as GHRP-6 (swine ED50 2.3 ± 0.03 nmol/kg vs 3.9 nmol/kg) but did not raise ACTH or cortisol above the GHRH baseline even at more than 200× the GH ED50 [1]. That is the selectivity that defines the molecule.
The GH it releases then feeds the liver's IGF-1 axis — though in short rodent studies IGF-1 is not always elevated, suggesting some effects are local and pulse-driven [4]. Ipamorelin also has peripheral actions: a direct, GH-independent insulinotropic effect on pancreatic islet tissue [13], and engagement of the brain's appetite circuitry typical of the ghrelin-agonist class [15].
The human pharmacokinetic data
The cleanest human dataset is a population PK/PD study in healthy male volunteers (n=8 per dose level) given five 15-minute IV infusions spanning 4.21–140.45 nmol/kg [2]. Kinetics were linear and dose-proportional, with a terminal half-life of approximately 2 hours, clearance 0.078 L/h/kg, and a steady-state volume of distribution 0.22 L/kg [2]. The growth-hormone response arrived as a single discrete pulse peaking around 0.67 h — about 40 minutes — after dosing [2]. This is one of the only human ipamorelin datasets in existence, and it is the basis for nearly every "how long does it last" statement on this site.
The one human efficacy trial — and it failed
Ipamorelin's defining human anchor is a single Phase 2 RCT (NCT00672074) in 114 adults undergoing bowel resection, given 0.03 mg/kg IV twice daily for up to 7 days [3]. It missed its primary endpoint: median time to first tolerated meal was 25.3 h with ipamorelin versus 32.6 h with placebo, which did not reach statistical significance (p=0.15) [3]. On safety, treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal emerged in that short perioperative window [3]. The honest reading: efficacy was not demonstrated, and the lack of any approval reflects failed efficacy programs, not merely incomplete development.
Preclinical efficacy: bone, body weight, and the 2024 ferret study
In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone-growth rate from 42 µm/day on vehicle to 44, 50, and 52 µm/day — with no change in total IGF-1, IGFBPs, or bone-turnover markers, pointing to a partly local, GH-pulse-driven skeletal effect [4]. NN703, an oral analog derived directly from ipamorelin, produced significant body-weight gain over 14 days in rats, confirming the class alters body composition via sustained GH-axis activation [7].
The most recent published in-vivo ipamorelin study, in 2024, used a ferret model: intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48–72 h), but had no anti-emetic effect on either acute or delayed emesis [5]. It reduced chemotherapy-associated weight loss through a peripheral mechanism while doing nothing for nausea — the freshest defensible finding in the literature.
Ipamorelin cjc-1295
Ipamorelin (a ghrelin-receptor peptide) and CJC-1295 (a GHRH analog) release GH through two different, complementary doors: ipamorelin via GHS-R1a, CJC-1295 via the GHRH receptor's cAMP pathway [1]. The rationale for pairing them is synergy — combining a GHRP with GHRH can produce GH release greater than the arithmetic sum of each alone, shown for the related peptide hexarelin plus GHRH in healthy men (true synergism, P=0.001) [9]. A 2026 orthopaedic review reports that CJC-1295 + ipamorelin improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while stressing that the evidence is limited to animal studies [18]. Critically, the combination itself has not been tested in a controlled human outcome trial — its support is single-agent pharmacology, not combination trials [3].
What is cjc 1295 ipamorelin
"CJC-1295 ipamorelin" (sometimes written without the hyphen) refers to the popular research combination of two distinct peptides — it is not a single approved product, and this site otherwise documents pure ipamorelin. CJC-1295 is a long-acting GHRH analog; ipamorelin is a selective ghrelin-receptor GH secretagogue [1]. Together they are promoted for sleep, recovery, and body composition, but the pairing's evidence base is extrapolated from each agent's separate pharmacology plus animal work [18]. No completed human trial has tested the combination for any clinical outcome [3].
Does cjc-1295 ipamorelin work
For raising GH acutely, the mechanisms are real: GHRP + GHRH co-administration produces synergistic GH release in humans, and prolonged GHRP-6 infusion more than doubled integrated GH while augmenting responses to GHRH boluses [10]. For clinical outcomes — fat loss, muscle, anti-aging — the answer is that it has not been demonstrated in controlled human trials [3]. A 2026 narrative review found CJC-1295 + ipamorelin improved muscle tetanic tension in a murine model but explicitly noted evidence is limited to animal studies [18]. So: a measurable hormonal effect, yes; proven human benefit, not yet.
Ipamorelin vs sermorelin
Ipamorelin and sermorelin sit on opposite sides of the GH-release pathway. Ipamorelin is a ghrelin-receptor (GHS-R1a) peptide [1]; sermorelin is a GHRH analog (it mimics growth-hormone-releasing hormone). They are sometimes combined precisely because a GHRP and a GHRH analog hit different receptors and can act synergistically [9]. The key safety distinction for this site: ipamorelin has never been an approved drug [3], whereas sermorelin had a different regulatory history as a GHRH analog. On selectivity, ipamorelin's signature is sparing cortisol and prolactin [1]; that is a property of the ghrelin-receptor mechanism, not the GHRH mechanism sermorelin uses.
Ipamorelin vs tesamorelin
Tesamorelin, like sermorelin, is a GHRH analog — it works on the GHRH receptor, not the ghrelin receptor that ipamorelin targets [1]. The mechanistic contrast is the same GHRP-versus-GHRH split: ipamorelin releases GH via GHS-R1a with a cortisol-sparing profile [1], while tesamorelin acts through the GHRH/cAMP pathway. From the safety lens this site leads with, the relevant fact is regulatory: ipamorelin has no approved indication and a failed Phase 2 trial [3], placing it in the non-approved-peptide group that recent reviews flag for absent long-term safety data [17]. Comparisons of GH secretagogues as a class consistently note that approved agents carry safety profiles from large trials that ipamorelin simply does not have [17].
Combination and class pharmacology
Several human studies clarify how GHRP-class peptides like ipamorelin behave when stacked. Chronic GHRP-2 or GHRH administration over 7–30 days converted an additive GHRP-2 + GHRH response into a synergistic one in younger and older adults, with the pattern depending on which agent was given chronically first [11]. And GHRP + GHRH synergy persisted even under high somatostatin tone that largely blunted GHRH alone — illustrating the somatostatin-overcoming advantage of the combination [12]. These are class-level principles (studied with hexarelin, GHRP-2, and GHRP-6, not ipamorelin specifically) that frame why ipamorelin is paired with GHRH analogs, while underscoring that ipamorelin's own combination data in humans are absent [3].